Poster Presentation at the American Association for Cancer Research Annual Meeting entitled “Efficacy of IMNN-001, an Interleukin-12 Immune Gene Therapy, at Different Dose Frequencies” by Dr. Jean Boyer, IMUNON’s Vice President – Preclinical R&D
Presentation at the World Vaccine & Immunotherapy Congress entitled “PLACCINE Nucleic Acid Vaccine Platform – Preclinical Proof of Concept Using a SARS-CoV-2 pDNA Construct” by Dr. Khursheed Anwer, IMUNON’s Chief Science Officer
Presentation at the 2022 World Vaccine Congress entitled “Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines” by Dr. Khursheed Anwer, Celsion’s Chief Science Officer
Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium Entitled “Phase I study of IL-12 plasmid administered in combination with NAC in patients with advanced stage ovarian cancer” by Dr. Premal H. Thaker, M.D., M.S.
Presentation at the American Association of Cancer Research (AACR) Special Conference entitled "Addressing Critical Questions in Ovarian Cancer Research and Treatment" by Dr. Khursheed Anwer, Celsion's executive vice president and chief scientific officer
Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Immunologic
Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Phase I st
Presentation at the 2016 American Association of Cancer Research (AACR) Annual Meeting during the Drug Delivery Session by Dr. Jason Fewell entitled "Interlukin-12 Gene therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubicin for Treatm
A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Pegylated Liposomal Doxorubicin) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Pr
Presentation at the Molecular Medicine TRI-Conference on February 20, 2015 by Dr. Khursheed Anwer titled "Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer."
experience while you navigate through the website. Out of these, the cookies
that are categorized as necessary are stored on your browser as they are
essential for the working of basic functionalities of the website. We also
use third-party cookies that help us analyze and understand how you use this
website. These cookies will be stored in your browser only with your
consent. You also have the option to opt-out of these cookies. But opting
out of some of these cookies may affect your browsing experience.